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ARTICLE
MEKK2 mediates aberrant ERK activation in
neurofibromatosis type I
Seoyeon Bok 1,8, Dong Yeon Shin1,2,8, Alisha R. Yallowitz1, Mark Eiseman1, Michelle Cung 1, Ren Xu3, Na Li3,
Jun Sun 1, Alfred L. Williams 4, John E. Scott 4, Bing Su5,6, Jae-Hyuck Shim 7 &
Matthew B. Greenblatt 1✉
Neurofibromatosis type I (NF1) is characterized by prominent skeletal manifestations caused
by NF1 loss. While inhibitors of the ERK activating kinases MEK1/2 are promising as a means
to treat NF1, the broad blockade of the ERK pathway produced by this strategy is potentially
associated with therapy limiting toxicities. Here, we have sought targets offering a more
narrow inhibition of ERK activation downstream of NF1 loss in the skeleton, finding that
MEKK2 is a novel component of a noncanonical ERK pathway in osteoblasts that mediates
aberrant ERK activation after NF1 loss. Accordingly, despite mice with conditional deletion of
Nf1 in mature osteoblasts (Nf1fl/fl;Dmp1-Cre) and Mekk2−/− each displaying skeletal defects,
Nf1fl/fl;Mekk2−/−;Dmp1-Cre mice show an amelioration of NF1-associated phenotypes. We
also provide proof-of-principle that FDA-approved inhibitors with activity against MEKK2 can
ameliorate NF1 skeletal pathology. Thus, MEKK2 functions as a MAP3K in the ERK pathway in
osteoblasts, offering a potential new therapeutic strategy for the treatment of NF1.
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Neurofibromatosis type I (NF1) is an autosomal dominantdisorder with an incidence of 1/3500, and ~50% ofpatients with NF1 display skeletal manifestations includ-
ing craniofacial dysmorphogenesis, osteopenia/osteoporosis, and
impaired fracture healing, including congenital pseudoarthroses.
The NF1 gene product, neurofibromin, is a Ras GTPase-activating
protein that functions as a negative regulator of Ras/ERK sig-
naling in the development and growth of a variety of tissues1.
Loss-of-function mutations in NF1 result in hyperactivation of
several signaling pathways, prominently including the MEK/ERK
pathway, and preclinical studies indicate utility for MEK/ERK
pathway inhibition for treating skeletal and other organ mani-
festations of NF12–4. Along these lines, ERK pathway inhibitors
have recently been shown to have clinical utility for the treatment
of a subset of plexiform neurofibromas in NF15. Despite this
promise, studies of ERK pathway inhibition in other clinical
contexts suggest that it can be associated with serious and likely
therapy limiting toxicities in a subset of patients, prominently
cardiovascular complications including myocardial infarction,
heart failure, cardiomyopathy, and hypertension6–8. These toxi-
cities are likely intrinsic to the broad importance of the ERK/
MAPK pathway in controlling fundamental cellular processes
such as proliferation and survival. Toxicity concerns are exacer-
bated when considering that therapy for skeletal manifestations of
NF1 would most plausibly entail long-term or even lifelong
treatment. Moreover, profound blockade of ERK pathway activity
is associated with severe osteopenia, raising concerns that non-
selective ERK pathway inhibition could actually exacerbate ske-
letal pathology in NF1, or at least that ERK pathway inhibition is
expected to have a narrow therapeutic window with regards to
skeletal endpoints9–11. To overcome these limitations, more
selective approaches are needed to target pathways mediating the
downstream effects of NF1 loss-of-function.
MAPKs operate in a three-tiered cascade: MAP kinase kinase
kinases (MAP3K), MAP kinase kinases (MAP2K), and MAPKs.
While the connections between MAP2Ks and MAPKs largely
occur in a stereotypical and invariant manner, the connections
between MAP3Ks and downstream MAP2Ks are much more
context-dependent, differing both among cell types and with
respect to specific stimuli. This suggests that inhibition of
MAP3Ks may offer a more selective and ultimately less toxic
means than directly targeting MAP2Ks or MAPKs to inhibit the
aberrant ERK pathway activation occurring downstream of NF1
loss-of-function. While MAP3Ks contributing to p38 and JNK
activation in osteoblasts, including ASK1 (MAP3K5)12 and TAK1
(MAP3K7)13,14, have been identified, the MAP3K mediating ERK
activation in osteoblasts is largely unknown, aside from studies
showing that MLK3 (MAP3K11) contributes to both ERK and
p38 activation and a study of RAF isoforms largely focused on
cartilage15,16. MEKK2 (MAP3K2) is a member of the MEK kinase
group of MAP3Ks, and early in vitro studies demonstrated that
MEKK2 has the ability to activate a number of downstream
MAPK pathways, including ERK1/2, JNK, p38, and ERK517–21.
We previously observed that MEKK2 mediated an alternative
pathway for the deubiquitination and stabilization of β-catenin in
osteoblasts and that MEKK2-deficient mice display significant
cortical and trabecular osteopenia due to impaired osteoblast
activity22.
Here we identify MEKK2 as a MAP3K contributing to ERK
pathway activation in osteoblasts and show that loss of MEKK2 is
sufficient to prevent the constitutive ERK activation occuring
in models of skeletal NF1. Accordingly, loss of MEKK2 can
ameliorate the skeletal manifestations occuring in a mouse model
of skeletal NF1. We also show that ponatinib, an FDA-approved
tyrosine-kinase inhibitor, can inhibit MEKK2 and that adminis-
tration of ponatinib significantly improves skeletal pathology in a
mouse model of skeletal NF1. This provides proof-of-principle for
targeting MEKK2 as a strategy for the management of the skeletal
manifestations of NF1.
Results
MEKK2 mediates ERK activation downstream of NF1 loss-of-
function. Given the ability of MEKK2 to activate the ERK
pathway in previous overexpression studies conducted in a non-
skeletal context17,21, we considered it as a candidate MAP3K
mediating ERK activation in osteoblasts. Immunoblotting showed
that ERK1/2 activation was markedly reduced in primary
Mekk2−/− calvarial osteoblasts (COBs), and, accordingly, that
phosphorylation of the well-characterized ERK substrates RSK2
and GSK3β was also reduced (Fig. 1a). RSK2 is known to in turn
phosphorylate and activate ATF4, a critical transcription factor
regulating the later stages of osteoblast differentiation23. Con-
sistent with this reduction in RSK2 activation, Mekk2−/− COBs
showed reduced activity of the ATF4-responsive osteoblast-spe-
cific cis-acting element 1 (OSE1)-luciferase reporter plasmid
(Fig. 1b). To provide direct biochemical confirmation of the
ability of MEKK2 to mediate ERK pathway activation, an in vitro
kinase assay was performed, showing that recombinant MEKK2
directly phosphorylated MEK1 and MEK2 (Fig. 1c). Thus,
MEKK2 contributes to basal ERK activation, and NF1 loss-of-
function via lentiviral Cre deletion in Nf1fl/fl osteoblasts induces
aberrant ERK activation (Fig. 1d). To examine aberrant ERK
activation downstream of NF1 loss-of-function in vivo, we gen-
erated mice with a conditional deletion of Nf1 in mature osteo-
blasts using dentin matrix acidic phosphoprotein 1-Cre (Dmp1-
Cre)24. Consistent with in vitro results, ERK was highly activated
in osteoblasts in the femurs of Nf1fl/fl;Dmp1-Cre mice compared
to Nf1fl/fl controls (Fig. 1e). We next examined if MEKK2 med-
iates ERK activation downstream of NF1 loss-of-function. Pre-
viously, we observed that FGF2 strongly activates MEKK2
phosphorylation in osteoblasts22. Indeed, knockdown of NF1 in
human mesenchymal stromal cell-derived osteoblasts resulted in
enhanced MEKK2 phosphorylation in response to FGF2, showing
that loss of NF1 can enhance MEKK2 activation (Fig. 1f). Simi-
larly, transduction of Nf1fl/fl osteoblasts with lentiviral Cre
increased MEKK2 phosphorylation as shown by either use of a
phos-tag gel or immunoblotting with anti-p-MEKK2 antibodies
(Fig. 1g). Immunohistochemistry for p-MEKK2 levels in cortical
bone was performed, finding that Nf1fl/fl;Dmp1-Cre mice showed
greater positivity for p-MEKK2-within bone adjacent mesench-
ymal cells (Fig. 1h). Likewise, knockdown of Nf1 enhanced ERK
activation by FGF2, and this enhancement was rescued by addi-
tional knockdown of Mekk2 (Fig. 1i). Thus, MEKK2 contributes
to the aberrant hyperactivation of ERK occurring with NF1 loss-
of-function in vitro.
MEKK2 deficiency rescues NF1-associated skeletal phenotypes.
Previously, Nf1fl/fl;Dmp1-Cre mice have been reported as a model
of skeletal NF1, finding that they display spontaneous fractures,
accompanied by reduced mechanical strength, low bone mineral
density, and high cortical porosity with an osteomalacia-like bone
phenotype25. Use of the Dmp1-Cre here has the advantage that it
avoids the severe growth and joint dysplasia phenotypes asso-
ciated with the deletion of NF1 in early osteoprogenitors/skeletal
stem cells as seen with Prx1 or Col2-Cre, which may complicate
interpretation of genetic or pharmacologic rescue
experiments26,27. In line with prior reports, we observed that
Nf1fl/fl;Dmp1-Cre mice display high cortical porosity and uneven
deposition of endosteal cortical bone. Based on our in vitro
findings, we hypothesized that additional deficiency for MEKK2
will ameliorate these phenotypes in Nf1fl/fl;Dmp1-Cre mice.
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Indeed, despite Mekk2−/− mice themselves being osteopenic and
having impaired bone formation, Nf1fl/fl;Mekk2−/−;Dmp1-Cre
mice displayed a substantial rescue of the Nf1fl/fl;Dmp1-Cre
phenotype, with normalization of cortical architecture and por-
osity (Fig. 2a, b), trabecular osteopenia (Fig. 2c, d) and calvarial
hypomineralization (Fig. 2e). In keeping with this, levels of
P1NP (procollagen type 1 N-terminal propeptide), a marker for
bone formation and osteoblast activity, were greatly increased in
Nf1fl/fl;Mekk2−/−;Dmp1-Cre mice compared to Nf1fl/fl;Dmp1-Cre
mice, whereas no significant difference was observed in levels of
CTX (Collagen type I C-terminal telopeptide), a marker of
osteoclast activity28. Similarly, FGF23, 25(OH) vitamin D, and
phosphate levels were all normalized in Nf1fl/fl;Mekk2−/−;Dmp1-
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Fig. 1 The MAP3K MEKK2 contributes to the aberrant ERK activation occurring with NF1 loss. a ERK phosphorylation levels were assessed by
immunoblotting in primary COBs isolated from Mekk2+/+ and Mekk2−/− mice. Cell lysates were immunoblotted with the indicated antibodies. b Primary
Mekk2+/+ and Mekk2−/− COBs were transfected with the OSE1-Luc (ATF4) reporter (n= 3 biologically independent samples). Mean ± s.e.m., unpaired,
two-tailed Student’s t test: **P < 0.01. c Purified unactivated GST-MEK1 or His-MEK2 was incubated with purified GST-MEKK2 and an in vitro kinase assay
was conducted. Two types of recombinant GST-tagged MEKK2 as indicated with a dagger and double dagger were used as described in the Methods
section. GST-MEK5 was used as a positive control. d Representative blot from three independent experiments. Primary Nf1fl/fl COBs infected with either
vector (Vec) or Cre lentivirus, were cultured for 7 days under differentiation conditions. Levels of NF1, phospho-ERK1/2, and ERK1/2 were analyzed by
immunoblotting. e Representative images of immunostaining for p-ERK (red) in femurs from 16 weeks old Nf1fl/fl and Nf1fl/fl;Dmp1-Cre mice. White arrows
indicate p-ERK positive osteoblasts. Nuclei are counterstained with DAPI (blue) and scale bar indicates 100 µm. Three independent fields were examined
per mouse (n= 3 mice per group). f human MSCs (hMSCs) were infected with shRNA lentiviruses expressing control (shCtrl) or NF1 (shNF1) targeting
shRNAs and stimulated with FGF2 (25 ng/ml) for the indicated times, then MEKK2 phosphorylation was analyzed by phos-tag electrophoresis. g MEKK2
phosphorylation was analyzed by either phos-tag electrophoresis or immunoblotting with p-MEKK2 antibody in primary Nf1fl/fl osteoblasts infected with
either vec or Cre lentivirus cultured for 14 days under differentiation conditions. All blotting was confirmed by at least three independent repeats. h
Immunohistochemistry for p-MEKK2 was performed in femurs from 16-week-old Nf1fl/fl and Nf1fl/fl;Dmp1-Cre mice. Scale bar denotes 100 µm. Three
independent fields were examined per mouse (n= 3 mice per group). i hMSCs were infected with the indicated shRNA lentiviruses and then stimulated
with FGF2 for the indicated times before immunoblotting, and ERK1/2 activation was analyzed by immunoblotting. Except where otherwise indicated, all
data shown are representative of at least two independent experiments. All unprocessed blots are provided in Supplementary Fig. 5. Source data are
provided as a Source Data file.
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with in vitro observations of MEKK2 acting downstream of
NF1 loss-of-function to mediate ERK pathway activation,
immunostaining confirmed that p-MEKK2, p-MEK1, and p-
ERK1/2 levels were strongly decreased in osteoblasts in femurs
of Nf1fl/fl;Mekk2−/−;Dmp1-Cre mice compared to Nf1fl/fl;Dmp1-
Cre mice (Fig. 2g). p-AKT levels were also analyzed by
immunostaining, but there were no significant differences among
these mice (Supplementary Fig. 1a). To explore impacts on the
osteocyte dendritic network, we performed filamentous actin (F-
actin) staining, finding clear disruption of the osteocyte dendritic
network in Nf1fl/fl;Dmp1-Cre mice. However, this aspect of the
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of rescue by additional MEKK2 deficiency (Supplementary
Fig. 1b). Thus, deficiency for MEKK2 ameliorates a wide range of
NF1-associated skeletal phenotypes in mice.
Ponatinib inhibits MEKK2 and ameliorates NF1 phenotypes.
Given this rescue, we hypothesized that pharmacological inhibi-
tion of MEKK2 could have clinical utility in treating the skeletal
manifestations of NF1. To maximize the translational relevance of
this study, we focused on identifying whether well-studied and
FDA-approved kinase inhibitors had activity against MEKK2,
focusing on a set of compounds previously studied in cell-free
assays with MEKK2, including AT9283, crizotinib, ponatinib, and
bosutinib29,30. By immunoblotting, we observed that ponatinib
strongly reduced MEKK2 phosphorylation (Fig. 3a–c) and further
observed that ERK activation was completely inhibited by
AT9283 and ponatinib in response to FGF2 (Fig. 3d, e). An
in vitro kinase assay using purified recombinant proteins con-
firmed that ponatinib inhibited both MEKK2 autopho-
sphorylation and MEKK2-mediated MEK1 phosphorylation in a
dose-dependent manner with an IC50 of ~100 nM (Fig. 3f). To
examine whether ponatinib phenocopies the effects of Mekk2
knockdown, mRNA levels were analyzed in NF1-deficient
osteoblasts during in vitro differentiation. Osteoblast-related
genes, including Osx, Runx2, Bsp, and Ocn were measured,
demonstrating that either Mekk2 knockdown or ponatinib
treatment both rescued or increased expression of osteoblast
marker genes (Fig. 3g).
To strengthen the evidence that these in vitro effects of
ponatinib to block MEKK2-mediated ERK pathway activation
downstream of NF1 loss-of-function truly reflect inhibition of
MEKK2, a compound with a distinct chemical scaffold expressly
identified as a MEKK2 inhibitor was examined (BRITE-719)31.
BRITE-719 had similar effects to those of ponatinib, strongly
inhibiting ERK phosphorylation (Fig. 3h). BRITE-690, an analog
of BRITE-719 lacking MEKK2 inhibitory activity, showed no
impact in these assays, further confirming that the effects
observed reflect inhibition of MEKK2.
After validating that ponatinib has the activity to inhibit
MEKK2, we next examined whether ponatinib can rescue the
skeletal phenotypes of Nf1fl/fl;Dmp1-Cre mice. To do this, we
administered ponatinib intraperitoneally in 11-week-old Nf1fl/fl;
Dmp1-Cre mice for 5 weeks. Similar to the effect of additional
MEKK2 deficiency on the Nf1fl/fl;Dmp1-Cre phenotype,
ponatinib-treated Nf1fl/fl;Dmp1-Cre mice displayed a clear rescue
of defects in cortical bone architecture (Fig. 4a, b), trabecular
osteopenia (Fig. 4c, d), and calvarial hypomineralization (Fig. 4e
and Supplementary Fig. 2) as compared to the vehicle
group. Similarly, ponatinib treatment elevated P1NP, 25(OH)
vitamin D, and phosphate levels relative to the levels in vehicle-
treated Nf1fl/fl;Dmp1-Cre mice (Fig. 4f). Similar to observations
made in vitro, Nf1fl/fl;Dmp1-Cre mice following administration
of ponatinib displayed significantly lower levels of p-MEKK2, p-
MEK1, and p-ERK1/2 in osteoblasts compared to vehicle
controls (Fig. 4g), but p-AKT levels were not changed
(Supplementary Fig. 3a). Osteocyte dendritic network morphol-
ogy was examined, but there was no clear evidence that ponatinib
rescued this aspect of the NF1 loss-of-function phenotype
(Supplementary Fig. 3b). As it may be clinically useful to target
NF1-related skeletal therapies to discrete temporal windows, such
as times of skeletal crisis, including fracture nonunion, or to
critical windows in skeletal development, the durability of
ponatinib effects were examined. Ponatinib treatment was
initiated at 4 weeks of age, continued for 5 weeks, and then a
phenotypes were assessed 7 weeks after drug withdrawal.
Ponatinib treatment had durable effects that persist after
treatment withdrawal under these conditions, including
effects to ameliorate cortical defects, though, as expected, the
magnitude of these effects was weaker than that seen with
ponatinib treatment continuing until the experimental endpoint
(Supplementary Fig. 4a–c). Taken together, these findings suggest
that MEKK2 is a key MAP3K-mediating ERK activation in
osteoblasts and that MEKK2 is a potential target for NF1
treatment.
Discussion
We here demonstrate rescue of the Nf1fl/fl;Dmp1-Cre phenotype
through genetic or pharmacologic inhibition of MEKK2. NF1
deficiency induces MEKK2 activation along with abnormal ERK
activation, and MEKK2 contributes to the aberrant ERK activa-
tion seen with NF1 loss-of-function via the ability of MEKK2 to
activate MEK1/2. MEKK2 also contributes to basal ERK activa-
tion, indicating that pathways other than those mediated
by canonical RAF isoforms play key roles in ERK activation in
osteoblasts. Despite Mekk2−/− mice displaying a low bone
mass phenotype, additional MEKK2 deficiency in osteoblast-
specific NF1-deficient mice dramatically improves NF1 skeletal
phenotypes, including cortical bone porosity, trabecular
bone mass, and endocrine disruptions related to calcium and
phosphate homeostasis. Finding evidence that two loss-of-
function alleles, each with strong deleterious phenotypes indivi-
dually result in a phenotype markedly less severe than either
alone when crossed provides clear evidence of epistasis, and
therefore support for the biochemical model that MEKK2 here
acts as a downstream mediator of the effects of NF1 deficiency in
osteoblasts. We also note that, while there are several models of
skeletal neurofibromatosis, each generated using different cre
lines and with different features, several of the MEKK2 or
ponatinib-dependent endpoints examined here, such as the cor-
tical porosity/endocortical pitting phenotype, are shared across
several models, including Nf1fl/fl;Prx-Cre26, Nf1fl/fl;Col2-Cre27,
Fig. 2 MEKK2 deficiency partially reverses NF1-associated skeletal pathology in mice. a Femurs from 16-week-old Nf1fl/fl, Nf1fl/fl;Mekk2−/−, Nf1fl/fl;Dmp1-
Cre, and Nf1fl/fl;Mekk2−/−;Dmp1-Cre mice were analyzed by μCT. b Quantitative parameters are porous volume, porosity (porous volume/total volume),
and porous surface from 16-week-old Nf1fl/fl (n= 5), Nf1fl/fl;Mekk2−/− (n= 8), Nf1fl/fl;Dmp1-Cre (n= 8), and Nf1fl/fl;Mekk2−/−;Dmp1-Cre (n= 10) mice.
Mean ± s.d., one-way ANOVA with Tukey’s multiple comparison test. c Representative μCT 3D-reconstuction images of trabecular bone in the distal femur
metaphysis. d Quantitative parameters include trabecular bone volume/total volume (BV/TV), thickness (Tb.Th), trabecular number (Tb.N), and spacing
(Tb.sp) in 16-week-old Nf1fl/fl (n= 8), Nf1fl/fl;Mekk2−/− (n= 6), Nf1fl/fl;Dmp1-Cre (n= 9), and Nf1fl/fl;Mekk2−/−;Dmp1-Cre (n= 8) mice. mean ± s.d., one-
way ANOVA with Tukey’s multiple comparison test. e μCT scans of mouse skulls at 16 weeks Nf1fl/fl, Nf1fl/fl;Mekk2−/−, Nf1fl/fl;Dmp1-Cre, and Nf1fl/fl;
Mekk2−/−;Dmp1-Cre mice. f Serum levels of P1NP, CTX, FGF23, PTH, 25(OH) vitamin D, and phosphate in 16-week-old mice. Data are represented as box
plots with the middle line representing the median, the box representing the 95% confidence interval of the median, and the whiskers representing the
range. Each dot represents a separate mouse. g Representative images and quantification of immunostaining for p-MEKK2 (green), p-MEK1 (magenta),
and p-ERK (red) in trabecular (left panels) and cortical bone (right panels) from 16-week-old Nf1fl/fl, Nf1fl/fl;Dmp1-Cre, and Nf1fl/fl;Mekk2−/−;Dmp1-Cre mice.
Nuclei are counterstained with DAPI (blue) and the scale bar indicates 100 µm. Three independent fields were examined per mouse (n= 3 mice per
group). mean ± s.d., one-way ANOVA with Tukey’s multiple comparison test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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and Nf1fl/fl;Osx-Cre32 mice, providing support for these findings
having relevance beyond the specific Dmp1-Cre based model
utilized here.
We here provide proof-of-concept that ponatinib (previously
known as AP24534) can ameliorate skeletal pathology associated
with NF1. In addition to the data offered in this study, support for
the proposed mechanism of ponatinib mediating its effects
through ERK pathway inhibition comes from studies finding that
MEK1/2 inhibition promoted bone healing in the context of NF1
deficiency2,33. Many NF1-associated skeletal phenotypes, except
a









































































































































































































































































































































































































































































































Fig. 3 Pharmacologic inhibition of MEKK2 prohibits ERK activation. a Primary COBs were immortalized through infection with a retrovirus expressing
SV40 large T-Antigen. COBs were pre-treated with the indicated inhibitors (1 µM, 30min), then stimulated with or without FGF2 (25 ng/ml, 20min) 30
min later. MEKK2 phosphorylation was analyzed by phos-tag electrophoresis. b MEKK2 phosphorylation was analyzed by either phos-tag electrophoresis
or immunoblotting with anti-p-MEKK2 in primary Nf1fl/fl osteoblasts infected with either vec or Cre lentivirus with the indicated inhibitors and
FGF2 stimulation. c hMSCs were treated with the indicated inhibitors, then MEKK2 phosphorylation was examined by phos-tag electrophoresis. d WT
immortalized COBs were lysed and immunoblotted for the indicated antibodies after inhibitor treatment. e Activation of ERK was detected in Saos-2 cells
after incubation with the indicated inhibitors and stimulation with or without FGF2. f Purified unactivated GST-MEK1 was incubated with purified GST-
MEKK2 and the indicated doses of ponatinib, and kinase activity of MEKK2 was analyzed by an in vitro kinase assay. g Expression levels of osteoblast genes
in primary Nf1fl/fl osteoblasts infected with either vec or Cre lentivirus. After infection, these cells are treated with the indicated inhibitors or a Mekk2-
targeting shRNA and cultured for 14 days (n= 4 biologically independent samples). mean ± s.d. h Saos-2 cells were treated with DMSO, ponatinib (1 µM),
BRITE-0600690 (BRITE-690, inactive compound), and BRITE-0600719 (BRITE-719, active compound) for 1 h with or without FGF2 stimulation.
Phosphorylation levels of ERK1/2 were assessed by immunoblotting. All data shown are representative of either two or three total independent
experiments. All unprocessed blots are provided in Supplementary Fig. 5. Source data are provided as a Source Data file.
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alterations in CTX levels, are rescued by ponatinib or MEKK2
deficiency. CTX levels not being regulated by MEKK2 is con-
sistent with observations that, despite showing robust skeletal
phenotypes, ablation of the ERK pathway in osteoblast lineage
cells does not significantly alter CTX levels9. Further work
has reported that MEK1/2 inhibition suppressed abnormal
expression of genes regulating PPi homeostasis in NF1-deficient
osteoblasts32. Thus, the findings here are broadly consistent
with the role of the ERK pathway in the skeletal pathogenesis
of NF1.
Ponatinib is currently approved by the FDA for patients with
Philadelphia chromosome positive (Ph+) chronic myeloid leu-
kemia (CML), particularly patients with tumors bearing the BCR-
ABL T315I resistance mutation, suggesting that currently
approved drugs may have an activity to ameliorate skeletal
manifestations of NF134. The clinical feasibility of using a
MEKK2 inhibitor, either ponatinib or an alternative with
increased specificity for MEKK2, is supported by observing that
early treatment of mice produces a relatively durable amelioration
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treatment discontinuation. Chemically, the activity of ponatinib
against MEKK2 observed here is overall consistent with obser-
vations that ponatinib displays relatively broad tyrosine-kinase
activity, including against FGFR, VEGFR, PDGFR, FLT3, and c-
Src, and it is possible or even probable that inhibition of non-
MEKK2 targets, or other unexpected mechanisms of ponatinib,
could have important contributions to the overall skeletal effects
of ponatinib observed here34–36. However, support for MEKK2
being at least one relevant target of ponatinib comes from finding
a very similar rescue of the Nf1fl/fl;Dmp1-Cre phenotype with
either ponatinib treatment or additional MEKK2 deficiency.
Additional support comes from observing that a small molecule
inhibitor of MEKK2 with a distinct chemical scaffold from
ponatinib, but not an analog of this compound lacking MEKK2
activity, recapitulates some of the in vitro effects of ponatinib on
ERK activation downstream of NF1 loss-of-function31.
However, any therapeutic promise of ponatinib must be
balanced against its toxicities, particularly concerns that ponati-
nib is associated with increased risk of arterial and venous
thrombosis in CML patients37. Given the broad tyrosine-kinase
activity of ponatinib, it is plausible or even likely that these
toxicities may be associated with ponatinib targets other than
MEKK2, suggesting that generation of analogs or novel chemo-
types with improved relative selectivity for MEKK2 over other
tyrosine kinases may allow the potential therapeutic effect of
ponatinib to be chemically dissected away from limiting toxicities.
Alternatively, strategies that focus on only providing transient
therapy to resolve the most severe clinical sequelae, such as
persistent nonunion after fracture, may offer a means to favorably
balance the benefits and toxicities of these agents. Support for this
strategy comes from studies that MEK1/2 inhibition can promote
healing after fracture in models of NF12,20. Additional support
comes from observing that the effects of ponatinib persist for
several weeks after therapy discontinuation, raising the possibility
that either intermittent or crisis-targeted MEKK2 inhibition could
have relatively durable overall effects on NF1-associated skeletal
phenotypes extending beyond the period of treatment. Any
consideration of the toxicities of either ponatinib or MEKK2
inhibition should be considered relative to alternative strategies,
such as the broad ERK pathway inhibition associated with MEK
inhibitors such as trametinib, which is potentially associated with
cardiomyopathy, hepatic toxicity, hypertension, rash, and inter-
stitial lung disease38. Both further preclinical and clinical studies
will be needed to explore these issues and determine the potential
utility of either ponatinib or alternative kinases inhibitors with
increased MEKK2 selectivity. Additionally, as NF1 is a multi-
system disorder, any novel therapeutic agent would have to be
integrated into a comprehensive strategy for management of these
complex patients.
We here identify MEKK2 as a mediator of aberrant ERK
activation in NF1-deficient mature osteoblasts. To the degree that
ERK is also implicated in the pathogenesis of other non-skeletal
manifestations of NF1, including benign neurofibromas and
malignant peripheral nerve sheath tumors39, this suggests that
evaluating the relative contributions of RAF isoforms versus
MEKK2 in these non-skeletal contexts and potential therapeutic
relevance of MEKK2 inhibition is warranted. Conversely, while
there is evidence that ERK is a key mediator of skeletal and non-
skeletal manifestations of NF1, several other pathways are acti-
vated downstream of NF1 loss-of-function, including PKA40,41. It
will be of interest to determine whether MEKK2 contributes to
the activation of these non-ERK pathways downstream of NF1
and also determine how inhibition of these alternative pathways
may contribute to NF1 therapy. MEKK2-independent pathways
acting downstream of NF1 are likely responsible for the few
aspects of the Nf1fl/fl;Dmp1-Cre phenotype not rescued by
MEKK2 or ponatinib, including alterations in CTX levels or
disruption of the osteocyte dendritic network. Given that MEKK2
can directly phosphorylate β-catenin and modulate its stability in
osteoblasts and that aberrant β-catenin activation has been pro-
posed as contributing to NF1-associated skeletal pathology22,42,
this raises the possibility that, in addition to ERK, β-catenin may
also contribute to the therapeutic effects downstream of MEKK2
deficiency or inhibition on NF1.
Methods
Animals. Floxed Nf1 (Nf1fl/fl) mice (Stock 017639) were purchased from Jackson
Laboratories. Generation of the Mekk2−/− mouse strain was described pre-
viously43. Transgenic mice expressing Cre recombinase under the control of the
Dmp1 promoter (Dmp1-Cre)44 were bred with Nf1fl/fl and/or Mekk2−/− mice. All
mice used were backcrossed more than six generations onto the C57BL/6 back-
ground. All mice were maintained on a C57Bl6/J background throughout the study.
All animals were maintained a 12 hr light/dark cycle, temperatures of 64–79 °F
(~18–26 °C) with 40–60% humidity in accordance with the NIH Guide for the Care
and Use of Laboratory Animals and were handled according to protocols approved
by the Weill Cornell Medical College subcommittee on animal care (IACUC).
Chemical reagents. Kinase inhibitors used were AT9283 (cat. no. S1134, Sell-
eckchem), crizotinib (PF-02341066) (cat. no. S1068, Selleckchem), ponatinib
(AP24534) (cat. no. S1490, Selleckchem), bosutinib (SKI-606) (cat. no. S1014,
Selleckchem), BRITE-0600690 (BRITE-690, inactive compound), and BRITE-
0600719 (BRITE-719, compound 1s, active compound)31.
Osteoblast culture and differentiation assays. Primary COBs were isolated from
5-day-old neonates by collagenase type II (cat. no. C6885, SigmaMillipore) and
dispase II (cat. no. 04942078001, Roche) digestion. Cells were cultured in differ-
entiation medium containing ascorbic acid and β-glycerophosphate. hMSCs were
cultured and differentiated into osteoblasts as described by the manufacturer
(Lonza). Primary COBs and Saos-2 cells were cultured in α-MEM medium (cat. no.
15-012CV, Cellgro) containing 10% FBS, 2 mM L-glutamine, 1% penicillin/strep-
tomycin, 1% HEPES, and 1% nonessential amino acids and differentiated with
Fig. 4 Inhibition of MEKK2 ameliorates skeletal defects in a mouse model of skeletal NF1. a Femurs from 16-week-old Nf1fl/fl mice treated with vehicle
(n= 4) or ponatinib (n= 5) and Nf1fl/fl;Dmp1-Cre mice treated with vehicle (n= 7) or ponatinib (n= 6) were analyzed by μCT. b Quantitative parameters
are porous volume, porosity (porous volume/total volume), and porous surface from vehicle (veh) and ponatinib-treated groups (pon) of Nf1fl/fl;Dmp1-Cre
mice. Mean ± s.d., one-way ANOVA with Tukey’s multiple comparison test. c Representative μCT 3D-reconstruction images of trabecular bone in the distal
femur metaphysis. d Relative quantitative analysis of trabecular BV/TV, thickness (Tb.Th), trabecular number (Tb.N), and spacing (Tb.sp) in vehicle (n=
8) and ponatinib-treated (n= 7) group of Nf1fl/fl;Dmp1-Cre. Mean ± s.d., unpaired, two-tailed Student’s t test. e μCT scans of mouse skulls in 16-week-old
Nf1fl/fl and Nf1fl/fl;Dmp1-Cremice treated with vehicle or ponatinib. f Serum levels of PINP, 25(OH) vitamin D, and phosphate in 16-week-old Nf1fl/fl and Nf1fl/
fl;Dmp1-Cre mice treated with vehicle (veh) or ponatinib (pon). Data are represented as box plots with the middle line representing the median, the box
representing the 95% confidence interval of the median, and the whiskers representing the range. Each dot represents a separate mouse. g Representative
immunofluorescent images and quantification for p-MEKK2 (green), p-MEK1 (magenta), and p-ERK (red) in femurs from 16-week-old Nf1fl/fl (WT) and
Nf1fl/fl;Dmp1-Cre mice treated with vehicle or ponatinib. Far right images show enlarged views of the dotted orange boxes. White arrows indicate signal
positive osteoblasts. Nuclei are counterstained with DAPI (blue) and the scale bar indicates 100 µm. Three independent fields were examined per mouse
(n= 3 mice per group). Mean ± s.d., one-way ANOVA with Tukey’s multiple comparison test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source
data are provided as a Source Data file.
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ascorbic acid and β-glycerophosphate. All cells were routinely tested to be myco-
plasma negative.
µCT analysis. µCT analysis was conducted on a Scanco Medical µCT 35 system at
the Citigroup Biomedical Imaging Core using the previously described15. Briefly, a
Scanco Medical μCT 35 system with an isotropic voxel size of 7 μm was used to
image the distal femur. Scans were conducted in 70% ethanol and used an X-ray
tube potential of 55 kVp, an X-ray intensity of 0.145 mA, and an integration time of
600 ms. µCT analysis was performed by an investigator blinded to the genotypes of
the animals under analysis. All endpoint µCT analysis was carried out on 16-week-
old mice.
In vitro kinase assay. In all, 200 ng of recombinant GST-tagged MEKK2 (Dagger,
cat. no. M0324, MilliporeSigma and Double dagger, cat. no. PV3822, Thermo-
Fisher) was incubated for 20 min at 30 °C in kinase buffer (20 mM Hepes (pH 7.5),
20 mM MgCl2, 1 mM EDTA, 2 mM NaF,2 mM glycerophosphate, 1 mM DTT, and
10 μM ATP) and 10 μCi of (γ-32P) ATP (cat. no. NEG502H250UC, PerkinElmer)
containing unactive GST-tagged MEK1 (cat. no. 14-420, MilliporeSigma), unactive
His-tagged MEK2 (cat. no. 14-532, MilliporeSigma), or GST-tagged MEK5 (cat. no.
A33380, ThermoFisher). The substrates then were resolved by SDS/PAGE, and
phosphorylated proteins were visualized by autoradiography. To assess MEKK2
kinase activity after ponatinib treatment, recombinant proteins were incubated
with serially diluted ponatinib for 20 min. Cell-free kinase assay conducted as
described above.
Immunoblotting. Cells were lysed in RIPA lysis buffer (10 mM Tris, 50 mM NaCl,
5 mM EDTA, 2 mM NaF, 30 mM Peptin, 5 μg/ml Aprotinin, and 1% Triton X-100)
supplemented protease and phosphatase inhibitor cocktail (cat. no. 78440, Ther-
moFisher), and the protein concentration was determined by BCA protein assay
reagent (cat. no. A53226, ThermoFisher). Proteins were separated by SDS-PAGE
and then electrophoretically transferred to PVDF membranes. Membranes were
incubated with a blocking buffer followed by incubation with primary and the
appropriate secondary antibodies and developed with ECL blotting substrate (cat.
no. 32134, ThermoFisher). Primary antibodies used were specific for NF1 (cat. no.
A300-140A, BETHYL), MEKK2 (cat. no. A302-163A, BETHYL), ERK1/2 (cat. no.
9102, Cell Signaling Technology), phospho-ERK1/2 (Thr202/Tyr204) (cat. no.
4377, Cell Signaling Technology), AKT (cat. no. 9272, Cell Signaling Technology),
phospho-AKT (Thr308) (cat. no. 13038, Cell Signaling Technology), phospho-p38
(Thr180/Tyr182) (cat. no. 9215, Cell Signaling Technology), phospho-RSK
(Ser380) (cat. no. 12032, Cell Signaling Technology), phospho-GSK-3β (Ser9) (cat.
no. 5558, Cell Signaling Technology), phospho-β-catenin (Ser675) (cat. no. 4176,
Cell Signaling Technology), JNK2 (cat. no. 9258, Cell Signaling Technology),
phospho-JNK (Thr183/Tyr185) (cat. no. 4668, Cell Signaling Technology), HSP90
(cat. no. sc-515081, Santa Cruz Biotechnology), and GAPDH (cat. no. sc-25778,
Santa Cruz Biotechnology). Primary antibodies were detected with goat anti-mouse
IgG HRP (cat no. 31430, Invitrogen) and goat anti-rabbit IgG HRP (cat no. 31460,
Invitrogen). The generation of the phospho-MEKK2 polyclonal antibody was
described previously21. To measure the levels of phosphorylated proteins, a Phos-
tag gel (cat. no. 192-18001, Wako) was used according to the manufacturer’s
instructions. All uncropped blot images are provided in Supplementary Fig. 5.
In vivo ponatinib treatment. Treatment was initiated in 11-week-old male and
female mice. Mice were administered ponatinib (25 mg/kg, intraperitoneal) (cat.
no. S1490, Selleckchem) daily for 5 weeks. Ponatinib was first dissolved in DMSO
at 100 mg/ml then resuspended in 30% PEG400+ 10% Triton X-100 in PBS. This
solution was also used as the vehicle control. To determine the durability of the
effects of ponatinib, treating mice starting at 4 weeks of age for 5 weeks and then
subsequently waiting 7 weeks before evaluating the phenotypes.
Serum assay. We analyzed mouse-PINP (cat. no. LS-F7173, LSBio), mouse-CTX
(cat. no. LS-F21349, LSBio), mouse-FGF23 (cat. no. LS-F31725-1, LSBio), mouse-
PTH (cat.no. LS-F23085-1, LSBio), mouse-Phosphate (cat. no. ab65622, Abcam),
and mouse-25(OH) Vitamin D (cat. no. ab213966, Abcam) by using a kit. All
ELISAs were run according to the manufacturer’s instructions.
Immunostaining. For immunofluorescence, femurs were harvested, embedded,
and cut into frozen sections, followed by rehydration with PBS. Samples were then
incubated with primary antibody against phospho-MEKK2 (Ser520; cat. no. PA5-
105898, Invitrogen), phospho-MEK1 (Thr286; cat. no. 9127, Cell Signaling Tech-
nology), phospho-ERK1/2 (Thr202/Tyr204; cat. no. 4370, Cell Signaling Tech-
nology), phospho-AKT (Ser473; cat. no. 4060, Cell Signaling Technology)
overnight at 4 °C, then washed three times with PBS. Secondary antibodies, goat
anti-rabbit IgG Alexa fluor 633 (cat no. A-21070, Invitrogen) were added to the
sample for 1 h followed by washing three times with PBS. Samples were finally
mounted with ProLong Gold antifade reagent with DAPI (cat. no. P36931, Invi-
trogen). For F-actin staining, fluorescent-conjugated phalloidin was used (cat. no.
A12379, Invitrogen). Imaging was performed with a Zeiss LSM 880 with Airyscan
high-resolution-detector confocal microscope. All immunofluorescence
experiments were quantified by examining at least three independent fields per
mouse (n= 3 mice per group). For histological analysis, femurs were dissected
from mice, fixed in 4% PFA for 24 h, and decalcified by daily changes of 15%
tetrasodium EDTA for 2 weeks and embedded and cut into frozen sections, fol-
lowed by rehydration with PBS. Decalcified sections were incubated with primary
antibodies to phospho-MEKK2 (Ser520) (cat. no. PA5-105898, Invitrogen) over-
night at 4 °C and then immunoreactivity was visualized using HRP substrate (cat.
no. SK-4805, Vector lab). Methyl green was used as counterstain.
qRT-PCR. Total mRNA was isolated from calvarial osteoblasts using TRIzol (cat.
no. 15596026, Invitrogen), and reverse transcription was performed with the High-
Capacity cDNA Reverse Transcription Kit (cat. no. 4368814, Applied Biosystems)
according to the manufacturer’s instructions. The primer sequences used in this
study are described in Supplementary Table 1.
Statistical analyses. All data are shown as the mean ± s.d. or mean ± s.e.m. as
indicated. For comparisons between two groups unpaired, two-tailed Student’s t
tests were used. For comparisons of three or more groups, one-way ANOVA was
used if normality tests passed, followed by Tukey’s multiple comparison test for all
pairs of groups. GraphPad PRISM v.7.04 was used for statistical analysis. P < 0.05
was considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, and
****P < 0.0001.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All relevant data are available from the authors. Source data are provided with this paper.
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